Gary L. Rosner
United States Food and Drug Administration(US)Johns Hopkins University(US)Johns Hopkins Medicine(US)Food and Drug Administration(TH)
Publications by Year
Research Areas
Statistical Methods in Clinical Trials, Bayesian Methods and Mixture Models, Statistical Methods and Inference, Acute Lymphoblastic Leukemia research, Cancer Genomics and Diagnostics
Most-Cited Works
- → Neoadjuvant PD-1 Blockade in Resectable Lung Cancer(2018)2,100 cited
- → Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma(2006)1,030 cited
- → MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer(2005)496 cited
- → Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline(2012)482 cited
- → Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia(2006)467 cited
- → Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes(2007)460 cited